Article Text

Download PDFPDF
Letter to the Editor
Copeptin levels upon corticosteroid treatment in acute community-acquired pneumonia
  1. Milica Popovic1,2,
  2. Claudine Angela Blum1,2,3,
  3. Mirjam Christ-Crain1,2
  1. 1 Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
  2. 2 Department of Clinical Research, University of Basel, Basel, Switzerland
  3. 3 Medical University Clinic, Department of General Internal and Emergency Medicine and Department of Endocrinology, Diabetology and Clinical Nutrition, Kantonsspital Aarau, Basel, Switzerland
  1. Correspondence to Milica Popovic, Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel 4031, Switzerland; milica.popovic{at}

Statistics from

In the past few years, copeptin, which is a stable surrogate marker for arginine vasopressin (AVP) activity, has emerged as a marker for disease severity and as a predictor for outcome in the setting of acute illness.1 2 Increased levels of copeptin have been shown in septic shock,1 acute stroke,3 in myocardial infarction,4 and in community-acquired pneumonia.5 However, little is known about the dynamics of copeptin levels in acute illness and about its response to anti-inflammatory treatment. Earliest evidence for corticosteroid-dependent regulation of AVP comes from studies dating back to 1967 showing that administration of corticosteroids reduced AVP levels in patients with adrenal cortisol deficiency. Furthermore, corticosteroid treatment was shown to reduce AVP expression in the posterior pituitary.6 7 In 2008, a first study addressed the question of corticosteroid-dependent AVP regulation in a human model of endotoxinemia.8 Thereby, pretreatment with corticosteroids dose dependently inhibited the increase in copeptin levels. However, no study so far has investigated the dynamics of copeptin in acute disease treated with and …

View Full Text


  • Contributors MP wrote the manuscript, analyzed the data and made substantial contributions to the design of the manuscript. CAB made substantial contributions to the acquisition of the data. MCC made substantial contributions to the concept and design of the manuscript. All authors approved the final version of the manuscript.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval Ethikkommission Nordwest- und Zentralschweiz.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.